Table 3. Time Taken for Achieving Complete Hematologic Response (THR) for Each CML Patient.

	duration of imatinib therapy (months)
	≤1.5	≤3	3–6	6–12
hematologic response (as per the National CML Society Guidelines) TLC (109/L) in the peripheral blood sample	no. of patients (N = 36)
major ≤ 12,000	12 (33.33%)	29 (80.56%)	32 (88.89%)	35 (97.22%)
partial (reduced but > 12,000)	24 (66.67%)	7 (19.44%)	4 (11.11%)	1 (2.78%)